Pharmacokinetic parameters of roflumilast and its active metabolite roflumilast N oxide after a single 500-mg dose of roflumilast in healthy Mexican subjects

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

An open-label, single-dose, single-centre study in healthy subjects.